Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4XD.L Regulatory News (C4XD)

  • There is currently no data for C4XD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

12 Mar 2021 07:00

RNS Number : 0278S
C4X Discovery Holdings PLC
12 March 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

C4X DISCOVERY HOLDINGS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Polar Capital LLP

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

10/03/2021

6. Date on which issuer notified (DD/MM/YYYY):

11/03/2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuervii

Resulting situation on the date on which threshold was crossed or reached

13.25%

13.25%

226,346,002

Position of previous notification (if

applicable)

15.26%

15.26%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BQQ2RV18

30,000,000.00

13.25%

SUBTOTAL 8. A

30,000,000.00

13.25%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Polar Capital Holdings PLC

%

%

%

Polar Partners Limited

%

%

%

Polar Capital US Holdings Limited

%

%

%

Polar Capital (America) Corporation

%

%

%

Polar Capital Holdings LLC

%

%

%

Phaeacian Partners Holdings LP

%

%

%

Polar Capital LLP

13.25%

%

13.25%

Phaeacian Partners LLC

%

%

%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, UK

Date of completion

11/03/2021

 

Annex: Notification of major holdings (to be filed with the FCA only)

A: Identity of the person subject to the notification obligation

Full name (including legal form for legal entities)

Contact address (registered office for legal entities)

E-Mail

Phone number / Fax number

Other useful information

(at least legal representative for legal persons)

B: Identity of the notifier, if applicable

Full name

Contact address

E-Mail

Phone number / Fax number

Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

 

 

Please send the completed form together with this annex to the FCA at the following email

address: Majorshareholdings@fca.org.uk. Please send in Microsoft Word format if possible.

Notes

 

i Please note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link: https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights held in the issuer shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold, please note that it might not be necessary to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFFFIIVDILLIL
Date   Source Headline
26th Apr 20247:00 amRNSCancellation - C4X Discovery Holdings plc
25th Apr 20247:00 amRNSLast day of dealings and update on cancellation
23rd Apr 20243:35 pmRNSHolding(s) in Company
19th Apr 20246:00 pmRNSC4X Discovery Holdings
15th Apr 202412:37 pmRNSResult of General Meeting
9th Apr 202410:58 amRNSDirector/PDMR Share Purchases
27th Mar 20247:00 amRNSProposed Voluntary Delisting
27th Mar 20247:00 amRNSInterim results
23rd Jan 20241:57 pmRNSResult of AGM
18th Jan 20247:00 amRNSBoard Update
4th Jan 20242:45 pmRNSHolding(s) in Company
3rd Jan 20247:00 amRNSAstraZeneca $11m milestone payment to C4XD
18th Dec 20233:31 pmRNSPosting of 2023 Annual Report and Notice of AGM
14th Dec 20237:00 amRNSFull Year Results
7th Dec 20237:00 amRNSNotice of Results
5th Oct 20232:35 pmRNSHolding(s) in Company
2nd Oct 202312:36 pmRNSBlock listing Interim Review
29th Sep 202311:14 amRNSGrant of Options and Directors Dealing
28th Sep 20233:52 pmRNSHolding(s) in Company
1st Sep 20237:00 amRNSTotal Voting Rights
18th Aug 202312:45 pmRNSExercise of Options, Issue of Equity and TVR
1st Aug 20237:00 amRNSDivestment of Orexin-1 to Indivior for £15.95m
20th Jun 20237:00 amRNSC4X Discovery Holdings plc: Board Change
1st Jun 20237:00 amRNSMALT-1 Inhibitor Programme Update
26th Apr 20237:00 amRNSHalf Year Results
19th Apr 20237:00 amRNSNotice of Results
8th Mar 20232:49 pmRNSBlock Listing Interim Review
22nd Feb 20237:00 amRNSC4XD and Garvan Institute collaboration
24th Jan 202311:47 amRNSResult of AGM
19th Jan 20237:00 amRNSMALT-1 Inhibitor Programme Update
10th Jan 20237:00 amRNSNick Ray Appointed as Chief Scientific Officer
19th Dec 20224:52 pmRNSPosting of 2022 Annual Report and Notice of AGM
15th Dec 20227:00 amRNSFull Year Results
28th Nov 20222:31 pmEQSC4X Discovery signs potential $402mln deal
28th Nov 20229:00 amRNSNotice of Final Results
28th Nov 20227:00 amRNSC4XD Agreement with AstraZeneca
1st Nov 20222:03 pmRNSExercise of Options, Issue of Equity and TVR
20th Oct 20227:00 amRNSC4XD and HitGen to collaborate in inflammation
4th Oct 20222:56 pmRNSHolding(s) in Company
22nd Sep 20224:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:35 pmRNSPrice Monitoring Extension
31st Aug 202211:10 amRNSHolding(s) in Company
17th Aug 20224:06 pmRNSHolding(s) in Company
17th Aug 20223:43 pmRNSHolding(s) in Company
16th Aug 20222:17 pmRNSHolding(s) in Company
11th Aug 202212:43 pmRNSResult of Placing to Raise £5.7 million
11th Aug 20227:00 amRNSProposed Placing to Raise Up To £5.7 million
2nd Aug 20227:00 amRNSBusiness Update
1st Aug 20223:09 pmRNSBlock Listing Interim Review
6th Jul 20227:00 amRNSC4X Discovery receives Sanofi milestone payment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.